Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

GeneCradle is the lead sponsor of 8 current clinical trials in our China register. 5 are recruiting patients now. The most common phase is Phase 1/2. The most-studied condition is Wilson Disease.

ClinicalTrials.gov trials by status

Recruiting563%
Not yet open113%
Active, closed225%

Trials by phase

Phase 1/2675%
Phase 1113%
Phase 3113%

Clinical trials sponsored by GeneCradle

8 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug NCT06391736 · ClinicalTrials.gov ↗ · Pompe Disease (Late-onset)	Phase 1/2	Recruiting	2024-04	China
Safety Evaluation of Gene Therapy Drug in the Treatment of Primary Hypertriglyceridemic Patients With Recurrent Pancreatitis NCT05860569 · ClinicalTrials.gov ↗ · Hypertriglyceridemia, Familial	Phase 1	Recruiting	2024-09	China
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients NCT05824169 · ClinicalTrials.gov ↗ · Spinal Muscular Atrophy	Phase 1/2	Recruiting	2023-02	China
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients NCT06421831 · ClinicalTrials.gov ↗ · Spinal Muscular Atrophy Type 3	Phase 1/2	Recruiting	2024-05	China
Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III NCT06971094 · ClinicalTrials.gov ↗ · SMA - Spinal Muscular Atrophy	Phase 3	Recruiting	2025-05	China
Phase I/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of GC310 Injection in Patients With Wilson's Disease (WD) NCT07173933 · ClinicalTrials.gov ↗ · Wilson Disease	Phase 1/2	Not yet open	2025-10	China
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients NCT05901987 · ClinicalTrials.gov ↗ · SMA II	Phase 1/2	Active, closed	2023-08	China
Evaluation of the Safety and Efficacy of Infantile-onset Pompe Disease Gene Therapy Drug NCT05793307 · ClinicalTrials.gov ↗ · Pompe Disease Infantile-Onset	Phase 1/2	Active, closed	2023-06	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Conditions in GeneCradle trials

8 conditions

Wilson Disease1Pompe Disease (Late-onset)1Hypertriglyceridemia, Familial1Spinal Muscular Atrophy1SMA II1Spinal Muscular Atrophy Type 31SMA - Spinal Muscular Atrophy1Pompe Disease Infantile-Onset1

By trial register

Register	Trials	Recruiting
Clinical trials in China	8	5

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Wilson Disease

Sponsor	Trials
Prime Medicine	2

Sponsors with the most current trials registered for this condition.

Questions about GeneCradle trials

How many clinical trials does GeneCradle sponsor?

GeneCradle is the lead sponsor of 8 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are GeneCradle trials recruiting?

Yes. 5 of its 8 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

GeneCradle clinical trials